

Takashi Nakamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8293728/publications.pdf>

Version: 2024-02-01

8
papers

128
citations

1684188
5
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

202
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Plasma Xanthine Oxidoreductase with Arterial Stiffness in Type 2 Diabetes with Liver Dysfunction. <i>American Journal of the Medical Sciences</i> , 2022, 363, 242-250.	1.1	3
2	The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data. <i>Journal of Clinical Hypertension</i> , 2022, 24, 1068-1075.	2.0	5
3	Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy. <i>FEBS Open Bio</i> , 2021, 11, 507-518.	2.3	2
4	GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1095-1105.	2.4	6
5	Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice. <i>Nutrition and Diabetes</i> , 2021, 11, 12.	3.2	6
6	Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice. <i>Obesity Science and Practice</i> , 2018, 4, 194-203.	1.9	22
7	Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice. <i>European Journal of Pharmacology</i> , 2016, 780, 224-231.	3.5	64
8	Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, <i>in vitro</i> and <i>in vivo</i> . <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 511-517.	4.4	20